ODO. B. Doronina

O. B. Doronina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O. B. Doronina has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global practical recommendations from the International Headache Society for the treatment of migraine attacks: an adapted Russian-language version

    by V. V. Osipova, M. A. Vinokurov, A. R. Artemenko, E. R. Lebedeva, A. V. Sergeev, Yu. E. Azimova, A. V. Amelin, L. R. Akhmadeeva, O. B. Doronina, E. V. Ekusheva, et al.

    The article was prepared by experts of the Russian Headache Society (RHS) and represents an adapted Russian-language version of the International Headache Society (IHS) Global practice recommendations for the treatment of migraine attacks, developed taking into account data from systematic reviews, meta-analyses and consensus documents. The recommendations have two levels: optimal – for countries and regions where most medicines are available, and basic – for regions with limited treatment options. Treatment algorithms using non-steroidal anti-inflammatory drugs, triptans, and gepants are presented, along with specific considerations for their use in special patient groups: pregnant women, the elderly, and patients with cardiovascular diseases. Medicines not registered in the Russian Federation and available alternatives are indicated. The adapted recommendations take into account the Russian specifics of drug availability and the clinical recommendations of the Ministry of Health of Russia. Compliance with the recommendations will improve the quality of care for patients with migraine in the Russian Federation.

  • Treatment of chronic nonspecific low back pain in spinal osteoarthritis: effectiveness of Ambene Bio combined with standard therapeutic approach

    by M.A. Bakhtadze, O.S. Davydov, A.E. Barulin, V.V. Gusev, F.I. Devlikamova, O.B. Doronina, P.P. Kalinsky, Yu.V. Karakulova, O.V. Kurushina, D.I. Lebedeva, et al.

    Objective. To evaluate the effect of treatment with Ambene Bio on chronic nonspecific LBP and spinal OA in patients with and without central sensitivity syndrome (CSS). Material and methods. The sample consisted of 120 patients with chronic nonspecific LBP and spinal OA with and without CSS. Results. Regardless of clinically significant CSS, reduction of LBP and functional activity after combined treatment with Ambene Bio showed significant improvements compared to standard treatment. Satisfaction with treatment was significantly higher after combined therapy. Conclusion. Treatment of chronic nonspecific lower back pain and spinal osteoarthritis has a clinical advantage when standard therapy is combined with Ambene Bio, as it significantly reduces pain, improves functional activity and contributes to higher satisfaction with treatment.

  • Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis

    by M.A. Bakhtadze, O.S. Davydov, A.E. Barulin, V.V. Gusev, F.I. Devlikamova, O.B. Doronina, P.P. Kalinsky, Yu.V. Karakulova, V.V. Kim, O.V. Kurushina, et al.

    Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.

  • Comparative study of the efficacy and safety of combined therapy with lornoxicam (Xefokam Rapid) and a nucleotide complex Xefomielyn in patients with exacerbation of chronic nonspecific low back pain

    by M.L. Kukushkin, Y.V. Karakulova, K.V. Vaitkus, O.B. Doronina, O.V. Vorobeva, K.A. Kolmakova, E.A. Lyakhova

    Objective. To evaluate the efficacy and safety of combined therapy with lornoxicam (Xefokam Rapid) and a nucleotide complex Xefomielyn compared to lornoxicam monotherapy in patients with exacerbation of chronic nonspecific low back pain (CNLBP). Material and methods. The study included 181 patients divided into a monotherapy group Xefokam Rapid and a combined therapy group with the addition of the nucleotide complex Xefomielyn. Pain intensity was assessed using the Numerical Rating Scale, functional status using the Roland—Morris Disability Questionnaire, recurrence rate, and treatment satisfaction. Results. Combination therapy provided a more pronounced reduction in pain intensity, a lower relapse rate, an improvement in functional status and higher satisfaction with treatment compared to monotherapy. Conclusion. The data obtained indicate high clinical efficacy and a favorable safety profile of combination therapy with Xefocam Rapid and Xefomyelin in patients with CLBP.


  • Resolution of the Council of Experts on the Treatment of Radiculopathy “New approaches to the treatment of back pain”

    by A.V. Amelin, E.A. Antipenko, E.R. Barantsevich, A.E. Barulin, Yu.N. Bykov, T.L. Vizilo, O.S. Davydov, F.I. Devlikamova, O.B. Doronina, N.V. Isaeva, et al.

    On November 08, 2024 in Moscow, under the auspices of the Russian Society for the Study of Pain (RSSP), a Council of Experts was held, during which leading specialists in the field of neurology, who have a high level of expertise in the treatment of back pain, discussed modern approaches to the therapy of discogenic lumbosacral radiculopathy (DLSR). The Council actualized the leading pathogenetic mechanisms of the disease onset and progression; discussed the mechanisms of pathogenesis, which are currently still insufficiently affected by pharmacotherapeutic intervention. Conservative therapy of DLSR is effective and allows to avoid surgical treatment in the majority (more than 90%) of cases. The leading role in conservative therapy of DLSR is played by informing the patient about the benign nature of DLSR, the possibility of spontaneous regression of disc herniation, methods of kinesiotherapy under the supervision of a specialist, epidural administration of local anesthetics and glucocorticoids in the acute period of the disease. In real practice, non-steroidal anti-inflammatory drugs, anticonvulsants are widely used, but their effectiveness remains controversial, so the search for new methods of conservative therapy is relevant. The experts noted the importance of the approach to the treatment of the problem under consideration from the position of its pathogenesis and discussed the introduction of new groups of drugs, emphasizing the need to expand clinical recommendations in favor of drugs with pathogenetically justified and complex mechanisms of action in back pain. The results of RCTs and the experience of clinical application of parenteral preparation of triterpene saponin escin — L-lysine escinate in different groups of patients with DLSR were discussed in detail. The expediency of conducting a multicenter placebo-controlled study of the efficacy of escin — L-lysine escinate in acute DLSR was noted.


  • Bioregulatory drug Newrexan in the treatment of anxiety and dissomnia. Resolution of the Council of Experts (June 8, 2023)

    by E.R. Barantsevich, O.V. Kurushina, L.R. Akhmadeeva, A.P. Skoromets, A.N. Belova, E.G. Mendelevich, V.V. Kovalchuk, O.B. Doronina, M.V. Barkhatov, P.R. Kamchatnov

    Bioregulatory drug Newrexan in the treatment of anxiety and dissomnia. Resolution of the Council of Experts.


  • Open Access

    Optimization of migraine attacks relief

    by G. R. Tabeeva, A. V. Amelin, L. R. Akhmadeeva, A. B. Danilov, O. B. Doronina, M. I. Koreshkina, N. V. Latysheva, E. G. Mendelevich, I. V. Sarvilina, A. V. Sergeev, et al.

    On December 24, 2022, in Moscow an interdisciplinary Council of Headache Experts, held under the auspice of the interregional public organization “Russian Society for the Study of Headache”, discussed the key problems of effective treatment of a migraine attack and the possibilities of a specific drug Kaporiza® (rizatriptan). Despite the development of strategies for the relief of migraine attacks and the effectiveness of triptans as first-line therapy, the choice of a specific drug in accordance with the individual clinical profile of the patient is difficult due to the existence of drugs in various forms (standard tablets, oral dispersible forms, injections, nasal sprays, rectal suppositories). Rizatriptan in the form of an orally dispersible tablet (ODT) has a number of advantages: high bioavailability, fast onset of action, and ease of use. Therefore, Kaporiza® (rizatriptan ODT) may be recommended as a priority therapy for all migraine patients who prefer the dispersible tablet form and who experience symptoms of nausea and vomiting, as well as for patients who have experience of poor efficacy and/or poor tolerability of other triptans. The Expert Council recommends to include rizatriptan ODT in the next edition of the clinical guidelines for the diagnosis and treatment of migraine as a first-line agent with Level A evidence.


  • Open Access

    Characteristics of sleep disorders in patients with chronic back pain

    by Daniil K. Vinogradov, O. B. Doronina

    Background. Insomnia is considered a risk factor for the frequency of pain, however, no reliable studies with a comprehensive analysis of the objective polysomnography data have been conducted so far. Objective. Using the method of polysomnography, to assess the changes in the structure of sleep in the chronic pain syndrome, by the example of chronic back pain. Methods. The study was carried out in two groups (basic and control,) in which the patients were examined according to the following algorithm: an objective examination, assessment of the neurological status, filling in neurological scales and questionnaires, a single comprehensive study of the night sleep (polysomnography). Results. According to the data of the polysomnographic study, presomnic disorders were detected in 25% of patients, intrasomnic disorders in 48%, and postsomnic disorders in 17%. Conclusion. These sleep patterns, measured by polysomnography, demonstrate a link between sleep disorders, changes in the psycho-vegetative status, and chronic pain syndrome.